Q4 2023 · 13F-HR
Paradigm Biocapital Advisors LPholdings as filed
Filed 2024-02-14 · accession 0001855655-24-000002
$2.14B
Reported value
30
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $283.9M | 13.3% | 3,858,008 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $203.1M | 9.51% | 3,658,624 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $160.8M | 7.53% | 422,577 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $137.8M | 6.45% | 2,385,857 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $114.0M | 5.34% | 1,894,644 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $110.9M | 5.19% | 7,903,600 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $104.4M | 4.89% | 4,794,488 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $99.3M | 4.65% | 1,453,883 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $98.8M | 4.63% | 2,330,508 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $98.0M | 4.59% | 2,127,400 | Common | SOLE |
| 60468T105 | MRTXEUR | MIRATI THERAPEUTICS INC | $90.7M | 4.24% | 1,543,116 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $82.3M | 3.85% | 2,312,919 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $81.2M | 3.80% | 12,611,335 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $67.0M | 3.14% | 3,707,001 | Common | SOLE |
| 641871108 | — | AMBRX BIOPHARMA INC | $62.0M | 2.90% | 4,352,689 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $60.5M | 2.83% | 3,176,743 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $44.3M | 2.07% | 351,700 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $38.3M | 1.79% | 931,303 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $37.1M | 1.74% | 2,171,419 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $29.8M | 1.40% | 1,091,779 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $22.5M | 1.05% | 2,136,339 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $20.8M | 0.97% | 1,025,000 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $19.8M | 0.93% | 2,265,988 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $18.2M | 0.85% | 1,262,828 | Common | SOLE |
| 142038108 | CRBU | CARIBOU BIOSCIENCES INC | $16.8M | 0.78% | 2,923,851 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $14.5M | 0.68% | 6,457,293 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $7.7M | 0.36% | 333,333 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $6.1M | 0.28% | 400,000 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $3.2M | 0.15% | 143,235 | Common | SOLE |
| 641871108 | — | AMBRX BIOPHARMA INC | $2.1M | 0.10% | 150,000 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.